top of page

Stefan Scherer, MD, PhD

Executive in Residence 

Stefan joined GSK as Global Head Experimental Medicine overseeing translational medicine, biomarkers, companion diagnostics, and clinical/translational alliances. He is responsible for strategic and operational aspects of personalized healthcare across Phase 1 to Phase 4. Prior, he held the position of SVP Clinical Development and CMO in Cellectis, clinical-stage biotech specializing in allogeneic CAR-Ts. In this role, he was responsible for setting the medical and clinical development strategy of multiple assets, in addition to building a clinical team. During his tenure, he brought​ programs in AML and ALL to the clinic and an IND approval for a target in MM. Previously, Stefan served as Vice President and Head of EDS&I (Early Development, Strategy, and Innovation) in Novartis. In this role, Stefan led broad teams, both in the medical and commercial functions, that planned and executed oncology studies for early-stage compounds, identify and implementing innovative signal seeking investigator-sponsored trials. Prior to this, Stefan served as Vice President, Global Head Correlative Sciences, Translational Precision Oncology where he was responsible for translational activities, biomarker and diagnostics assay development of targeted therapies, immunotherapies, and cell-based therapies in both solid tumors and hematology. Before joining Novartis, Stefan worked at Biocartis as the CMO responsible for the assay development and diagnostic strategy of the company. For over six years, Stefan held positions of increasing responsibility at F. Hoffmann-La Roche/ Genentech, starting as the biomarker program leader for Avastin and soon after overseeing the biomarker work for the entire angiogenesis franchise. Stefan later served as Head Biomarkers and Translational Medicine in Pharma Development overseeing the biomarker, diagnostic, translational medicine in late-stage Oncology. During his tenure, he worked closely with external partners in academia and commercial entities to established multiple translational hubs to further accelerate scientific discoveries.  Stefan received his M.D. from the University of Freiburg and University of Saarbruecken/ Homburg Medical School, Germany, and his Ph.D. in Biomedical Sciences from the University of Wuerzburg - Biocenter, Wuerzburg, Germany. Stefan earned a post-graduate degree in Bioinformatics from the Academy for postgraduate education with the Universities of Heidelberg and Mannheim, Germany.

bottom of page